74 related articles for article (PubMed ID: 24894093)
1. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
[TBL] [Abstract][Full Text] [Related]
2. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
[TBL] [Abstract][Full Text] [Related]
5. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
Kao CJ; Wurz GT; Lin YC; Vang DP; Griffey SM; Wolf M; DeGregorio MW
Cancer Immunol Res; 2015 Jul; 3(7):741-50. PubMed ID: 25672395
[TBL] [Abstract][Full Text] [Related]
7. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
Mitchell P; Thatcher N; Socinski MA; Wasilewska-Tesluk E; Horwood K; Szczesna A; Martín C; Ragulin Y; Zukin M; Helwig C; Falk M; Butts C; Shepherd FA
Ann Oncol; 2015 Jun; 26(6):1134-1142. PubMed ID: 25722382
[TBL] [Abstract][Full Text] [Related]
8. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
[TBL] [Abstract][Full Text] [Related]
9. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
10. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.
Vang DP; Wurz GT; Griffey SM; Kao CJ; Gutierrez AM; Hanson GK; Wolf M; DeGregorio MW
J Vis Exp; 2013 Oct; (80):e50868. PubMed ID: 24300078
[TBL] [Abstract][Full Text] [Related]
11. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.
Comella G; Frasci G; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Ruffolo P; Comella P
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-113-S12-116. PubMed ID: 9331134
[TBL] [Abstract][Full Text] [Related]
15. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
16. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
[TBL] [Abstract][Full Text] [Related]
17. Repurposing ospemifene for potentiating an antigen-specific immune response.
Kao CJ; Wurz GT; Lin YC; Vang DP; Phong B; DeGregorio MW
Menopause; 2017 Apr; 24(4):437-451. PubMed ID: 27922937
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
[TBL] [Abstract][Full Text] [Related]
20. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C; Eberhardt W; Graupner B; Theegarten D; Gauler T; Freitag L; Abu Jawad J; Wohlschlaeger J; Welter S; Stamatis G; Stuschke M
Eur J Cancer; 2013 Jun; 49(9):2107-15. PubMed ID: 23510803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]